GILEAD SCIENCES, INC.
GILDNasdaq · SIC 2836
$134.28
↓ -1.5%Jul 17 close · end-of-day
Price
1Y↑ +25.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$168.4B
Enterprise Value
$190.5B
P/E
18.3
P/S
5.7
P/B
7.2
EV/EBITDA
17.7
PEG
0.8
FCF Yield
6.1%
Dividend Yield
2.4%
Revenue (TTM)
$29.7B
Net Income (TTM)
$9.2B
Free Cash Flow (TTM)
$10.2B
Gross Margin
—
Operating Margin
34.9%
Net Margin
31.0%
ROE
39.2%
ROIC
19.5%
Debt / Equity
0.9
Net Cash
-$22.2B
Return 1Y
+26.6%
Company profile
Gilead Sciences discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, and Atripla products for the treatment of HIV/AIDS.
- CEO
- Daniel P. O'Day
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 17,000
- Headquarters
- California
- Website
- gilead.com
Management & directors
- Dickinson Andrew DChief Financial Officer
- Mercier JohannaChief Comm & Corp Aff Officer
- O'Day Daniel PatrickChairman & CEO
- Berger DietmarChief Medical Officer
- Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp
- Telman Deborah HEVP, Corporate Affairs & GC
- Wilfong Diane E.Interim Corp Controller & CAO
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-08-06
GILD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$7.0B↑ +4.4%
Diluted EPS$1.61↑ +54.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $24.7B | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $4.1B | $9.9B | $7.3B | $7.6B | $1.7B | $10.0B |
| Net income | $123.0M | $6.2B | $4.6B | $5.7B | $480.0M | $8.5B |
| Diluted EPS | $0.10 | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
| Operating cash flow | $8.2B | $11.4B | $9.1B | $8.0B | $10.8B | $10.0B |
| Free cash flow | $7.5B | $10.8B | $8.3B | $7.4B | $10.3B | $9.5B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 16.5% | 36.3% | 26.9% | 28.0% | 5.8% | 34.0% |
| Net margin | 0.5% | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.0B | $7.5B | $7.6B | $6.7B | $7.1B | $7.8B | $7.9B | $7.0B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $2.6B | $888.0M | $2.5B | $2.2B | $2.5B | $3.3B | $2.0B | $2.6B |
| Net income | $1.6B | $1.3B | $1.8B | $1.3B | $2.0B | $3.1B | $2.2B | $2.0B |
| Diluted EPS | $1.29 | $1.00 | $1.43 | $1.04 | $1.56 | $2.43 | $1.75 | $1.61 |
| Operating cash flow | $1.3B | $4.3B | $3.0B | $1.8B | $827.0M | $4.1B | $3.3B | $2.5B |
| Free cash flow | $1.2B | $4.2B | $2.8B | $1.7B | $720.0M | $4.0B | $3.1B | $2.4B |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 38.0% | 11.8% | 32.4% | 33.6% | 34.9% | 42.8% | 25.0% | 37.2% |
| Net margin | 23.2% | 16.6% | 23.6% | 19.7% | 27.7% | 39.3% | 27.5% | 29.0% |
Company news
Jul 17, 2026
Jul 16, 2026
Jul 15, 2026
Jul 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Dickinson Andrew D· Chief Financial Officer | Sale | 3,000 | $129.93 | $389,776.80 | filing |
| 2026-07-15 | Mercier Johanna· Chief Comm & Corp Aff Officer | Sale | 3,000 | $129.92 | $389,757.60 | filing |
| 2026-07-01 | O'Day Daniel Patrick· Chairman & CEO | Sale | 11,900 | $126.09 | $1.5M | filing |
| 2026-07-01 | O'Day Daniel Patrick· Chairman & CEO | Sale | 3,100 | $127.08 | $393,932.50 | filing |
| 2026-06-15 | Dickinson Andrew D· Chief Financial Officer | Sale | 3,000 | $125.40 | $376,200.00 | filing |
| 2026-06-15 | Mercier Johanna· Chief Comm & Corp Aff Officer | Sale | 1,480 | $123.42 | $182,656.57 | filing |
| 2026-06-15 | Mercier Johanna· Chief Comm & Corp Aff Officer | Sale | 1,070 | $124.00 | $132,675.51 | filing |
| 2026-06-15 | Mercier Johanna· Chief Comm & Corp Aff Officer | Sale | 450 | $125.40 | $56,430.00 | filing |
| 2026-06-10 | O'Day Daniel Patrick· Chairman & CEO | Tax withholding | 4,213 | $121.48 | $511,795.24 | filing |
| 2026-06-10 | Dickinson Andrew D· Chief Financial Officer | Tax withholding | 1,341 | $121.48 | $162,904.68 | filing |
| 2026-06-10 | Mercier Johanna· Chief Comm & Corp Aff Officer | Tax withholding | 1,341 | $121.48 | $162,904.68 | filing |
| 2026-06-10 | Cain Wettan Keeley M· EVP Gen Counsel, Legal & Comp | Tax withholding | 283 | $121.48 | $34,378.84 | filing |
| 2026-06-10 | Berger Dietmar· Chief Medical Officer | Tax withholding | 263 | $121.48 | $31,949.24 | filing |
| 2026-06-10 | Mercier Johanna· Chief Comm & Corp Aff Officer | Option exercise | 2,796 | — | — | filing |
| 2026-06-10 | Berger Dietmar· Chief Medical Officer | Option exercise | 533 | — | — | filing |
| 2026-06-10 | Cain Wettan Keeley M· EVP Gen Counsel, Legal & Comp | Option exercise | 589 | — | — | filing |
| 2026-06-10 | Dickinson Andrew D· Chief Financial Officer | Option exercise | 2,796 | — | — | filing |
| 2026-06-10 | O'Day Daniel Patrick· Chairman & CEO | Option exercise | 8,779 | — | — | filing |
| 2026-06-01 | O'Day Daniel Patrick· Chairman & CEO | Sale | 10,900 | $131.10 | $1.4M | filing |
| 2026-06-01 | O'Day Daniel Patrick· Chairman & CEO | Sale | 3,062 | $132.22 | $404,842.64 | filing |
| 2026-06-01 | O'Day Daniel Patrick· Chairman & CEO | Sale | 1,038 | $132.97 | $138,020.58 | filing |
| 2026-05-26 | GILEAD SCIENCES, INC. | Award | 471,698 | $26.50 | $12.5M | filing |
| 2026-05-15 | Mercier Johanna· Chief Comm & Corp Aff Officer | Option exercise | 25,000 | $66.64 | $1.7M | filing |
| 2026-05-15 | Mercier Johanna· Chief Comm & Corp Aff Officer | Sale | 11,177 | $131.19 | $1.5M | filing |
| 2026-05-15 | Mercier Johanna· Chief Comm & Corp Aff Officer | Sale | 8,374 | $132.23 | $1.1M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.